Evidence map›Paper›PMID 32791124›Full record

ArticleAmerican journal of obstetrics and gynecology2020

Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms.

Krystal Thomas-White, Susanne Taege, Roberto Limeira, Cynthia Brincat, Cara Joyce, Evann E Hilt, Laura Mac-Daniel, Katherine A Radek, Linda Brubaker, Elizabeth R Mueller and 1 more

4 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in American journal of obstetrics and gynecology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02524769 nacompletednot on this map

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

TypeinterventionalSponsorLoyola UniversityRan2015 to 2017Enrolled27ConditionsOveractive BladderArmsconjugated estrogen
NCT02835846 phase4completednot on this map

Investigation of the Effect of the Female Urinary Microbiome on Incontinence

TypeinterventionalSponsorLoyola UniversityRan2016 to 2018Enrolled35ConditionsOveractive Bladder, Incontinence, NocturiaArmsEstrogen Cream
NCT05557279 phase2completednot on this mapstarted 2023, after this paper: background citation

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks - a Single-center Study

TypeinterventionalSponsorLoyola UniversityRan2023 to 2025Enrolled53ConditionsOveractive BladderArms500 mg NDS-446
NCT06633705 phase4completednot on this mapstarted 2023, after this paper: background citation

Investigation of the Effects of Local Estrogen Administration on Vaginal, Periurethral and Urinary Microbiota in Genitourinary Syndrome

TypeinterventionalSponsorKoc University HospitalRan2023 to 2024Enrolled31ConditionsGenitourinary Syndrome of MenopauseArmsVaginal Cream with Applicator
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. HPV vaccination associates withFrontiers in microbiology · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Role of Vaginal Microbiota and OralBioengineering (Basel, Switzerland) · 2025
    Article
  12. Article
  13. Genome sequences for nineMicrobiology resource announcements · 2025
    Article
  14. Review
  15. Complete genome sequence ofMicrobiology resource announcements · 2025
    Article
  16. Complete genome sequence of vaginal swab isolateMicrobiology resource announcements · 2025
    Article
  17. Review
  18. State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Krystal Thomas-WhiteDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA.
Susanne TaegeObstetrics and Gynecology and Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Mount Carmel Medical Group, Mount Carmel Urogynecology and Pelvic Floor, Westerville, OH.
Roberto LimeiraDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Loyola Genomics Facility, Loyola University Chicago, Maywood, IL.
Cynthia BrincatObstetrics and Gynecology and Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL.
Cara JoycePublic Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Evann E HiltDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA.
Laura Mac-DanielSurgery, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Katherine A RadekDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Surgery, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Linda BrubakerObstetrics and Gynecology and Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, San Diego, CA.
Elizabeth R MuellerObstetrics and Gynecology and Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Alan J WolfeDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Loyola Genomics Facility, Loyola University Chicago, Maywood, IL. Electronic address: awolfe@luc.edu.
Loyola University Chicago · USMount Carmel Health · USRush University Medical Center · USUniversity of California, Los Angeles · US

Funding

The Female Urinary Microbiome and Urinary IncontinenceR01DK104718 · NIDDK · LOYOLA UNIVERSITY CHICAGO · PI BRUBAKER, LINDA, WOLFE, ALAN J · 2016 to 2020
$3.1M
The Female Urinary Microbiome and Urinary IncontinenceR56DK104718 · NIDDK · LOYOLA UNIVERSITY CHICAGO · PI BRUBAKER, LINDA, WOLFE, ALAN J · 2015 to 2015
$300k
NIDDK NIH HHS R01 DK104718NIDDK NIH HHS R56 DK104718
6 · The paper itself

Abstract

backgroundPrevious work has shown that the vaginal microbiome decreases in Lactobacillus predominance and becomes more diverse after menopause. It has also been shown that estrogen therapy restores Lactobacillus dominance in the vagina and that topical estrogen is associated with overactive bladder symptom improvement. We now know that the bladder contains a unique microbiome and that increased bladder microbiome diversity is associated with overactive bladder. However, there is no understanding of how quickly each pelvic floor microbiome responds to estrogen or if those changes are associated with symptom improvement.

objectiveThis study aimed to determine if estrogen treatment of postmenopausal women with overactive bladder decreases urobiome diversity. STUDY

designWe analyzed data from postmenopausal participants in 2 trials (NCT02524769 and NCT02835846) who chose vaginal estrogen as the primary overactive bladder treatment and used 0.5 g of conjugated estrogen (Premarin cream; Pfizer, New York City, NY) twice weekly for 12 weeks. Baseline and 12-week follow-up data included the Overactive Bladder questionnaire, and participants provided urine samples via catheter, vaginal swabs, perineal swabs, and voided urine samples. Microbes were detected by an enhanced culture protocol. Linear mixed models were used to estimate microbiome changes over time. Urinary antimicrobial peptide activity was assessed by a bacterial growth inhibition assay and correlated with relative abundance of members of the urobiome.

resultsIn this study, 12 weeks of estrogen treatment resulted in decreased microbial diversity within the vagina (Shannon, P=.047; Richness, P=.043) but not in the other niches. A significant increase in Lactobacillus was detected in the bladder (P=.037) but not in the vagina (P=.33), perineum (P=.56), or voided urine (P=.28). The change in Lactobacillus levels in the bladder was associated with modest changes in urgency incontinence symptoms (P=.02). The relative abundance of the genus Corynebacterium correlated positively with urinary antimicrobial peptide activity after estrogen treatment.

conclusionEstrogen therapy may change the microbiome of different pelvic floor niches. The vagina begins to decrease in diversity, and the bladder experiences a significant increase in Lactobacillus levels; the latter is correlated with a modest improvement in the symptom severity subscale of the Overactive Bladder questionnaire.

Indexed as

MicrobiotaActinomycesAdministration, IntravaginalAgedAntimicrobial Cationic PeptidesBiodiversityChromatography, High Pressure LiquidCorynebacteriumEstrogensEstrogens, Conjugated (USP)FemaleHumansLactobacillusMiddle AgedPostmenopauseStreptococcusAntimicrobial Cationic PeptidesEstrogensEstrogens, Conjugated (USP)16S rRNA gene sequencingantimicrobial peptidesenhanced urine cultureestrogenoveractive bladderurgency urinary incontinenceurinary microbiomeurinary urgencyvaginal microbiome

Identifiers

PMID32791124
PMCPMC7609597
OpenAlexW3048947650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.